Overview
Celea Therapeutics is a lung-focused drug developer working on therapies for pulmonary disease, with a lead effort centered on a pulmonary fibrosis drug entering a pivotal test. Its target market includes patients and clinicians addressing serious lung conditions. The company’s disclosed differentiator is its focused pulmonary strategy and progression of a fibrosis candidate to a late-stage clinical milestone. Celea raised $180 million in an undisclosed round announced in July 2026 to support that pivotal test.
Funding History
Lung-Focused Celea Secures $180M for Pivotal Test of Pulmonary Fibrosis Drug
Frequently Asked Questions
- How much has Celea Therapeutics raised in total?
- Celea Therapeutics has raised a total of $180M across 1 funding round.
- What does Celea Therapeutics do?
- Celea Therapeutics is a lung-focused drug developer working on therapies for pulmonary disease, with a lead effort centered on a pulmonary fibrosis drug entering a pivotal test. Its target market includes patients and clinicians addressing serious lung conditions. The company’s disclosed differentiator is its focused pulmonary strategy and progression of a fibrosis candidate to a late-stage clinical milestone. Celea raised $180 million in an undisclosed round announced in July 2026 to support that pivotal test.
- Where is Celea Therapeutics headquartered?
- Celea Therapeutics is headquartered in San Francisco, CA.
Related Insights
A comprehensive analysis of Sage's funding history, investors, competitive position, and growth trajectory in the AI Healthcare space.
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $35.9 billion raised across 95 deals, with 15 mega-rounds capturing 85.5% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.